Oppenheimer Sees 440% Upside in Acrivon Therapeutics as Key ACR-368 Data Approaches
Cancer drug ACR-368 shows strong early results in endometrial trials biomarker-driven response.
/ 2 items
Cancer drug ACR-368 shows strong early results in endometrial trials biomarker-driven response.
Acrivon Therapeutics (ACRV) announces clinical trial data for experimental cancer drugs ACR-368 and ACR-2316, but significant challenges remain with limited cash runway and unproven efficacy.